Alternatives to Xarelto (Rivaroxaban) for Anticoagulation

Primary Direct Oral Anticoagulant (DOAC) Alternatives

The American College of Cardiology recommends apixaban 5 mg twice daily as the strongest alternative to Xarelto, demonstrating superior efficacy with fewer strokes, systemic emboli, and major bleeding events compared to warfarin in the ARISTOTLE trial of 18,201 patients 1
Apixaban represents the preferred alternative with the strongest evidence for superiority over warfarin, while rivaroxaban only demonstrated noninferiority 1
Dosing is 5 mg twice daily for most indications including VTE treatment and stroke prevention in atrial fibrillation, with only 27% undergoing renal elimination, making it safer in renal impairment compared to other DOACs 2
For patients with gastric or gastroesophageal lesions, apixaban may be safer than edoxaban or rivaroxaban, with major bleeding occurring in 9 patients with GI cancer in each treatment group when compared to dalteparin 2
The American Heart Association suggests stopping apixaban at least 48 hours before high-bleeding-risk procedures and 24 hours before low-bleeding-risk procedures 1

Warfarin remains a legitimate alternative when DOACs are contraindicated or not tolerated, requiring INR monitoring with target range of 2.0-3.0 for most indications, and allowing for easy monitoring of anticoagulation intensity via INR, unlike DOACs 2, 4

The National Comprehensive Cancer Network recommends LMWHs over DOACs in patients with gastric and gastroesophageal tumors due to increased hemorrhage risk with DOACs in this population, particularly important for cancer-associated VTE where bleeding risk is elevated 2

The American College of Cardiology states that prosthetic heart valves or hemodynamically significant valve disease are absolute contraindications to DOACs, as well as advanced liver disease with coagulopathy, pregnancy, and breastfeeding, and severe renal impairment varies by agent 1, 3, 5

The European Society of Cardiology recommends renal function assessment at least annually in patients with normal or mild renal impairment, and 2-3 times per year in patients with moderate renal impairment, as declining kidney function affects drug clearance and bleeding risk 1, 4
Adherence to DOACs is critical due to their short half-lives, and no routine coagulation monitoring means adherence cannot be easily verified, with the American Heart Association suggesting that patients who miss doses may be at risk of thromboembolism 1, 4

The American College of Cardiology recommends prothrombin complex concentrate (PCC) 50 IU/kg for emergency reversal of factor Xa inhibitors when specific agents are unavailable, and idarucizumab specifically reverses dabigatran, while no specific antidotes exist for apixaban or edoxaban 1, 4

The European Society of Cardiology suggests that no bridging therapy with LMWH is required for the majority of interventions given the rapid onset and offset of action, and DOACs can be restarted as soon as effective hemostasis is achieved, with anticoagulant effect evident within hours 1, 4

The American Heart Association recommends aspirin alone (81-325 mg daily) ONLY for patients who cannot take any oral anticoagulant, as it provides inadequate stroke protection in high-risk patients, and the combination of aspirin and clopidogrel carries bleeding risk similar to warfarin and is not recommended as a substitute for anticoagulation 1, 3

The American College of Cardiology advises against combining DOACs with antiplatelet agents without clear indication, as safety and effectiveness have not been established, and against using standard coagulation tests (PT, aPTT) for dose adjustment of DOACs, as these are non-specific and not validated for this purpose 1, 3, 4